{
  "id": 3071612,
  "title": "FDA Approves First Alzheimer's Blood Test For Americans As Young As 40",
  "url": "https://urgent.news/2026/08/24/fda-approves-first-alzheimers-blood-test-for-americans-as-young-as-40",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-24T17:00:00.000Z",
  "source": {
    "name": "Slashdot",
    "slug": "slashdot",
    "url": "https://science.slashdot.org/story/26/08/24/1637252/fda-approves-first-alzheimers-blood-test-for-americans-as-young-as-40"
  },
  "original_language": "en",
  "account": "The FDA has authorized the first Alzheimer's blood test, PrecivityAD2, capable of detecting the disease in symptomatic patients as young as 40. The test analyzes plasma AB42/40 and p-tau217/np-tau217 proteins through mass spectrometry, providing a score that categorizes results as negative, likely positive, or positive for Alzheimer's. Isobel Coleman, CEO of the Alzheimer's Drug Discovery Foundation, highlighted the significance of this development, stating that sustained investment in translational science is crucial in bringing promising ideas from the laboratory to patients. In a recent clinical validation study involving 1,142 symptomatic adults, PrecivityAD2 accurately identified 97.6% of positive biomarkers, maintaining consistent results even in patients with conditions like chronic kidney disease and diabetes that could skew plasma amyloid samples. It is important to emphasize that the test is not designed for routine health screenings, but rather for patients exhibiting cognitive decline. As tools like PrecivityAD2 become more prevalent in clinical practice, they will facilitate earlier Alzheimer's detection, enhance clinical trials, and lay the groundwork for precision medicine and combination therapies.",
  "summary": "The FDA has cleared the first Alzheimer's blood test for symptomatic patients as young as 40. The test measures amyloid and tau biomarkers from a single blood draw and identified positive biomarkers with 97.6% accuracy in a validation study. New Atlas reports: PrecivityAD2 is a single blood test that quickly assesses the proteins amyloid and tau, using mass spectrometry to measure plasma AB42/40…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}